文章：

血清BCMA水平可预测MGUS和冒烟型骨髓瘤患者的预后

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients

原文发布日期：2021-06-24

DOI: 10.1038/s41408-021-00505-4

类型: Article

开放获取: 是

英文摘要：

Soluble BCMA (sBCMA) levels are elevated in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). However, the association between sBCMA levels and prognosis in MGUS and SMM has not been studied. We retrospectively analyzed sBCMA levels in stored samples from 99 MGUS and 184 SMM patients. Baseline sBCMA levels were significantly higher in MGUS and SMM patients progressing to MM during clinical follow up. When stratified according to the median baseline sBCMA level for each cohort, higher levels were associated with a shorter PFS for MGUS (HR 3.44 comparing sBCMA ≥77 vs <77 ng/mL [95% CI 2.07–5.73, p < 0.001] and SMM (HR 2.0 comparing sBCMA ≥128 vs <128 ng/mL, 95% 1.45–2.76, p < 0.001) patients. The effect of sBCMA on PFS was similar even after adjusting for the baseline MGUS or SMM risk stratification. We evaluated paired serum samples and found that sBCMA increased significantly in MGUS and SMM patients who eventually progressed to MM, whereas among MGUS non-progressors the sBCMA level remained stable. While our results require independent validation, they suggest that sBCMA may be a useful biomarker to identify MGUS and SMM patients at increased risk of progression to MM independent of the established risk models.
 

摘要翻译： 

在意义未明的单克隆丙种球蛋白病（MGUS）和冒烟型多发性骨髓瘤（SMM）患者中，可溶性BCMA（sBCMA）水平升高。然而，sBCMA水平与MGUS和SMM预后之间的关联尚未得到研究。我们回顾性分析了99例MGUS和184例SMM患者储存样本中的sBCMA水平。在临床随访期间进展为多发性骨髓瘤（MM）的MGUS和SMM患者中，基线sBCMA水平显著更高。按各队列中位基线sBCMA水平分层后，较高水平与较短的MGUS（sBCMA≥77纳克/毫升对比<77纳克/毫升的风险比[HR]为3.44，95%置信区间2.07–5.73，p<0.001）和SMM（sBCMA≥128纳克/毫升对比<128纳克/毫升的HR为2.0，95%置信区间1.45–2.76，p<0.001）患者无进展生存期相关。即使在调整基线MGUS或SMM风险分层后，sBCMA对无进展生存期的影响仍然相似。我们评估了配对血清样本，发现最终进展为MM的MGUS和SMM患者的sBCMA显著增加，而在未进展的MGUS患者中，sBCMA水平保持稳定。尽管我们的结果需要独立验证，但它们表明sBCMA可能是一种有用的生物标志物，可用于识别进展为MM风险较高的MGUS和SMM患者，且独立于现有风险模型。

原文链接：

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients